KK Women's and Children's Hospital

kkh.com.sg

Total trials

132

Active

47

Phase 3

15

Total enrollment

87,784

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 14 of 14 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Letrozole2
Mifepristone1
Ropivacaine3
Fentanyl3
Morphine2
Entonox1
Meperidine1
Ultiva1
Anti-CD19 CAR T-cells1
Bu Shen Yi Jing Pill1
Benzydamine Hydrochloride1
Phenylephrine3
Ephedrine3
Glycerin Suppository1

Next readouts

  • 2017-05-30
  • 2019-05-06
  • 2021-07-19
  • 2024-12-31
  • 2025-08
  • 2025-12
  • 2025-12
  • 2025-12-31
  • 2025-12-31
  • 2025-12-31

Top conditions

  • Metabolic Disease6
  • Anxiety6
  • Gestational Diabetes5
  • Pain5
  • Pregnancy5
  • Anesthesia4
  • Fertility Issues3
  • Breast Cancer3

Frequently asked questions about KK Women's and Children's Hospital

How many clinical trials does KK Women's and Children's Hospital have on ClinicalTrials.gov?
KK Women's and Children's Hospital is listed as the lead sponsor on 132 clinical trials in ClinicalTrials.gov, 47 of which are currently active (recruiting, enrolling, or ongoing).
How many of KK Women's and Children's Hospital's trials are in Phase 3?
15 of KK Women's and Children's Hospital's trials are in Phase 3, spread across 14 active drug programs.
What therapeutic areas does KK Women's and Children's Hospital focus on?
KK Women's and Children's Hospital's most-studied conditions on ClinicalTrials.gov are Metabolic Disease, Anxiety, Gestational Diabetes, Pain, Pregnancy.
When are KK Women's and Children's Hospital's next clinical trial readouts?
KK Women's and Children's Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Vital-signs-integrated Patient-assisted Intravenous Opioid Analgesia”, expected around 2017-05-30.